Moen M H, Hagen B, Onsrud M
Department of Obstetrics and Gynaecology, National Hospital, University of Oslo, Norway.
Hum Reprod. 1991 Nov;6(10):1400-3. doi: 10.1093/oxfordjournals.humrep.a137277.
This study was performed to evaluate CA 125 in peritoneal fluid as an indicator of endometriosis. Peritoneal fluid from patients with mostly minimal and mild endometriosis (n = 43) and normal controls (n = 17) was collected at laparoscopy or laparotomy. The median concentration of CA 125 in peritoneal fluid did not differ significantly between patients and controls (79 IU/ml versus 76 IU/ml). In patients with endometriosis, a significantly increasing concentration of CA 125 in peritoneal fluid was seen from the early follicular to the late luteal phase; a similar change was not observed in the controls. In 14 patients, peritoneal fluid was sampled again after treatment with danazol and a significant reduction in median CA 125 concentration (76.5 IU/ml versus 57 IU/ml), peritoneal fluid volume (17.5 ml versus 10.5 ml) as well as reduced endometriosis scores (4 versus 2) were found. In controls, the concentration of CA 125 was about 10 times higher in peritoneal fluid than in serum. As the peritoneal levels of CA 125 did not differ significantly between patients with endometriosis and controls and as the reduction seen after danazol treatment did not correlate with the decrease of endometriotic implants, it is concluded that the monitoring of CA 125 in peritoneal fluid will not be useful in the diagnosis or control of endometriosis.
本研究旨在评估腹腔液中CA 125作为子宫内膜异位症指标的价值。在腹腔镜检查或剖腹手术时，收集了大多为轻度和中度子宫内膜异位症患者（n = 43）及正常对照者（n = 17）的腹腔液。患者和对照者腹腔液中CA 125的中位浓度无显著差异（分别为79 IU/ml和76 IU/ml）。在子宫内膜异位症患者中，从卵泡早期到黄体晚期，腹腔液中CA 125浓度显著升高；而对照组未观察到类似变化。14例患者经达那唑治疗后再次采集腹腔液，结果发现CA 125中位浓度显著降低（从76.5 IU/ml降至57 IU/ml），腹腔液体积减少（从17.5 ml降至10.5 ml），子宫内膜异位症评分也降低（从4分降至2分）。在对照组中，腹腔液中CA 125浓度约为血清中的10倍。由于子宫内膜异位症患者与对照者腹腔液中CA 125水平无显著差异，且达那唑治疗后CA 125浓度降低与子宫内膜异位种植灶减少无关，因此得出结论：监测腹腔液中CA 125对子宫内膜异位症的诊断或病情监测并无帮助。
